ArticleFrontiers in molecular biosciences2026
Impact of EGFR variant allele frequency on treatment-related adverse events in patients with metastatic NSCLC treated with osimertinib.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osimertinib is an approved first-line therapy for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). However, beyond the identification of common EGFR mutations, additional pathological or molecular factors that predict treatment response, survival outcomes, or toxicity remain limited. Materials and Methods: This retrospective study analyzed data from a registry of NSCLC patients with EGFR mutations treated with first-line osimertinib between March 2017 and December 2024. Variant allele frequency (VAF) was evaluated as a potential predictive factor for overall survival (OS), progression-free survival (PFS), and adverse events (AEs). Results: Among 147 eligible patients, the mean OS was 25.5 months and the mean PFS was 21.4 months. Patients with VAF ≥30% exhibited improved outcomes compared to those with VAF <30%, with mean OS of 31.4 months versus 19.7 months (p = 0.022), and mean PFS of 25.0 months versus 18.2 months (p = 0.234). Similar trends were observed across EGFR exon 19 deletion and exon 21 L858R subgroups (p = 0.056). When comparing toxicity profiles, the overall AE rates were similar between high-VAF and low-VAF patients. However, several statistically significant differences were noted: diarrhea (21.3% vs. 5.7%, p = 0.005) and dyspnea (16.4% vs. 3.4%, p = 0.0085) were more frequent in the high-VAF group, while anemia (9.2% vs. 3.3%, p = 0.03) and creatinine elevation (5.7% vs. 1.6%, p = 0.01) occurred more commonly in the low-VAF group. Conclusion: Higher EGFR VAF was significantly associated with improved overall survival in patients with EGFR-mutated NSCLC treated with first-line osimertinib and showed a numerical trend toward longer progression-free survival. Similar patterns were observed across key molecular subgroups. Additionally, this study is the first to report potential VAF-related differences in adverse event patterns, suggesting that VAF may have relevance not only for efficacy but also for toxicity characterization. These findings support the potential role of VAF as a prognostic biomarker in EGFR-mutant NSCLC and warrant further prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.